GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone ...

USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...